熱門資訊> 正文
MacroGenics扩大了与Sagard的ZYNYZ特许权使用费协议，预付6000万美元
2026-05-04 20:50
- MacroGenics (NASDAQ: MGNX) on Monday said it has entered into an expanded royalty purchase agreement with Sagard Healthcare Partners tied to global sales of its drug ZYNYZ.
- MacroGenics said it will receive $60 million upfront and could get up to $20 million in additional sales-based milestone payments in 2026 under the amended agreement.
- The deal grants Sagard a capped royalty interest in future global net sales of ZYNYZ, with rights reverting to MacroGenics once Sagard receives up to 1.7 times its investment by September 2032, or 2.0 times thereafter.
- ZYNYZ, a PD-1 inhibitor, was originally developed by MacroGenics and licensed to Incyte Corporation under a global collaboration agreement.
- Source: Press Release
More on MacroGenics
- MacroGenics: Oncology Opportunities In Play, But Investing Feels Like A Gamble
- MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- MacroGenics gains removal of FDA partial hold on lead program
- Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant
- Seeking Alpha’s Quant Rating on MacroGenics
推薦文章
騰訊、阿里等中概巨頭業績來襲！AI收入轉化率成核心看點，這輪財報季能否助力恆科「反彈」？
港股周報 | 存儲芯片持續飆升！兩倍做多海力士周內狂漲64%；段永平重大調倉！清倉中國神華，大幅買入泡泡瑪特
一周財經日曆 | 下周重磅大事齊襲！特朗普政府或攜黃仁勛訪華；中概科網股財報季打響！騰訊、阿里同日放榜
美股機會日報 | 「TACO」已經過時？華爾街瘋狂湧入「NACHO」交易；今晚20:30！美國4月非農或創年內最大落差？
華盛早報 | 美伊突發交火！特朗普密集發聲施壓；英偉達官宣入股，IREN盤后一度暴漲27%
5月8日外盤頭條：美國計劃本周重啟護航行動 特朗普給予歐盟至7月4日批准貿易協議 OpenAI與博通芯片豪賭遇冷
CoreWeave一季度末簽約總電力容量3.5吉瓦 年內股價漲近80%
馬斯克再下注：SpaceX IPO倒計時 擬投1190億美元建Terafab芯片廠
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
